NeuroPace Continues to Strengthen Management Team
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has appointed Amy Treadwell as its new Vice President of Human Resources. CEO Joel Becker emphasized the importance of this appointment in supporting the company's growth and capitalizing on commercial, operating, and technological opportunities. Ms. Treadwell brings significant experience from healthcare and technology roles, having previously served as VP of People at CyCognito and held HR leadership positions at Carbon Health, Fitbit, and eBay.
This appointment, along with recent additions of Brett Wingeier as VP of Research and Development and Katie Keller as VP of Marketing, aims to strengthen NeuroPace's management team and enhance its strategy to increase access, adoption, and utilization of RNS therapy. Ms. Treadwell holds a Juris Doctor degree from Santa Clara University School of Law and a Bachelor's degree in International Relations from the University of Southern California.
NeuroPace, Inc. (Nasdaq: NPCE), un'azienda di dispositivi medici focalizzata sul trattamento dell'epilessia, ha nominato Amy Treadwell nuovo Vice Presidente delle Risorse Umane. Il CEO Joel Becker ha sottolineato l'importanza di questa nomina nel sostenere la crescita dell'azienda e nel capitalizzare sulle opportunità commerciali, operative e tecnologiche. La signora Treadwell porta con sé una significativa esperienza dai settori della salute e della tecnologia, avendo precedentemente ricoperto il ruolo di VP delle Persone in CyCognito e avendo occupato posizioni di leadership nelle risorse umane presso Carbon Health, Fitbit ed eBay.
Questa nomina, insieme all'aggiunta recente di Brett Wingeier come VP di Ricerca e Sviluppo e Katie Keller come VP di Marketing, ha l'obiettivo di rafforzare il team di management di NeuroPace e migliorare la propria strategia per aumentare l'accesso, l'adozione e l'utilizzo della terapia RNS. La signora Treadwell detiene un titolo di Juris Doctor presso la Santa Clara University School of Law e una laurea in Relazioni Internazionali presso l'Università della California del Sud.
NeuroPace, Inc. (Nasdaq: NPCE), una empresa de dispositivos médicos centrada en el tratamiento de la epilepsia, ha designado a Amy Treadwell como nueva Vicepresidenta de Recursos Humanos. El CEO Joel Becker destacó la importancia de esta designación para apoyar el crecimiento de la empresa y capitalizar las oportunidades comerciales, operativas y tecnológicas. La Sra. Treadwell aporta una experiencia significativa en roles de atención médica y tecnología, habiendo sido previamente Vicepresidenta de Personas en CyCognito y ocupando posiciones de liderazgo en recursos humanos en Carbon Health, Fitbit y eBay.
Esta designación, junto con los recientes nombramientos de Brett Wingeier como Vicepresidente de Investigación y Desarrollo y Katie Keller como Vicepresidenta de Marketing, tiene como objetivo fortalecer el equipo directivo de NeuroPace y mejorar su estrategia para aumentar el acceso, la adopción y la utilización de la terapia RNS. La Sra. Treadwell posee un título de Juris Doctor de la Santa Clara University School of Law y una licenciatura en Relaciones Internacionales de la Universidad del Sur de California.
NeuroPace, Inc. (Nasdaq: NPCE), 간질 치료에 중점을 둔 의료기기 회사가 Amy Treadwell을 새로운 인사부 부사장으로 임명했습니다. CEO Joel Becker는 이 임명이 회사의 성장 지원과 상업적, 운영적, 기술적 기회를 활용하는 데 중요하다고 강조했습니다. Treadwell 씨는 CyCognito에서 인사 VP로 근무한 경험을 포함하여 의료 및 기술 분야에서 중요한 경험을 갖고 있습니다. 그녀는 또한 Carbon Health, Fitbit 및 eBay에서 인사 리더십 직책을 역임했습니다.
이 임명은 Brett Wingeier를 연구개발 부사장으로, Katie Keller를 마케팅 부사장으로 최근 추가한 것과 함께 NeuroPace의 관리팀을 강화하고 RNS 치료의 접근성, 채택 및 활용을 증가시키기 위한 전략을 향상시키고자 하는 목표를 가지고 있습니다. Treadwell 씨는 산타클라라 대학교 법대에서 법학 박사 학위를, 남가주 대학교에서 국제관계 학사를 소지하고 있습니다.
NeuroPace, Inc. (Nasdaq: NPCE), une entreprise de dispositifs médicaux axée sur le traitement de l'épilepsie, a nommé Amy Treadwell nouvelle vice-présidente des ressources humaines. Le PDG Joel Becker a souligné l'importance de cette nomination pour soutenir la croissance de l'entreprise et tirer parti des opportunités commerciales, opérationnelles et technologiques. Mme Treadwell apporte une expérience significative dans les secteurs de la santé et de la technologie, ayant précédemment été VP des personnes chez CyCognito et ayant occupé des postes de direction en ressources humaines chez Carbon Health, Fitbit et eBay.
Cette nomination, ainsi que les récentes recrues de Brett Wingeier en tant que VP de la recherche et du développement et de Katie Keller en tant que VP du marketing, vise à renforcer l'équipe de direction de NeuroPace et à améliorer sa stratégie pour accroître l'accès, l'adoption et l'utilisation de la thérapie RNS. Mme Treadwell possède un diplôme de Juris Doctor de la Santa Clara University School of Law et un diplôme de premier cycle en relations internationales de l'Université de Californie du Sud.
NeuroPace, Inc. (Nasdaq: NPCE), ein Unternehmen für medizinische Geräte, das sich auf die Behandlung von Epilepsie konzentriert, hat Amy Treadwell zur neuen Vizepräsidentin für Personalwesen ernannt. CEO Joel Becker betonte die Bedeutung dieser Ernennung zur Unterstützung des Unternehmenswachstums und zur Nutzung kommerzieller, betrieblicher und technologischer Chancen. Frau Treadwell bringt umfassende Erfahrung aus dem Gesundheits- und Technologiesektor mit, nachdem sie zuvor als VP für Personal bei CyCognito tätig war und Führungspositionen im Personalwesen bei Carbon Health, Fitbit und eBay innehatte.
Diese Ernennung, zusammen mit den jüngsten Neuankömmlingen Brett Wingeier als VP für Forschung und Entwicklung und Katie Keller als VP für Marketing, zielt darauf ab, das Managementteam von NeuroPace zu stärken und die Strategie zur Erhöhung des Zugangs, der Akzeptanz und der Nutzung der RNS-Therapie zu verbessern. Frau Treadwell hat einen Juris Doctor von der Santa Clara University School of Law und einen Bachelor-Abschluss in internationalen Beziehungen von der University of Southern California.
- Appointment of experienced HR leader Amy Treadwell as VP of Human Resources
- Recent additions to management team in key roles (R&D and Marketing)
- Strategic focus on increasing access, adoption, and utilization of RNS therapy
- None.
Appoints experienced people leader as Vice President of Human Resources
MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately.
“We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth,” said Joel Becker, Chief Executive Officer of NeuroPace. “We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy’s appointment, along with the recent appointments of Brett Wingeier as Vice President of Research and Development and Katie Keller as Vice President of Marketing, helps position us to take full advantage of these opportunities and execute our strategy of increasing access, adoption, and utilization of RNS therapy.”
“I am excited to join NeuroPace and look forward to developing our people to help the company capitalize on the many great opportunities ahead,” stated Ms. Treadwell.
Ms. Treadwell brings significant experience and a track record of success in healthcare and technology roles to NeuroPace. Most recently, she served as the Vice President of People at cyber security start-up CyCognito, and prior to that held human resources leadership positions at Carbon Health, Fitbit and eBay. Ms. Treadwell has a Juris Doctor degree from the Santa Clara University School of Law and a Bachelor of Arts degree in International Relations from the University of Southern California.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace’s current expectations, forecasts and beliefs; future financial performance, including management’s continued outlook for fiscal year 2024; the Company’s commitment to effectively managing its operating expenses; ability to capitalize on increased market opportunities by expanding access to treatments; and clinical trial results and indication expansion. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties related to market acceptance and adoption of NeuroPace’s RNS System; risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System; the risk that NeuroPace may not realize the intended benefits of its partnership with DIXI Medical; risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace’s RNS System; NeuroPace’s reliance on contractors and other third parties, including single-source suppliers and vendors; and other important factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 13, 2024, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
Who is the new Vice President of Human Resources at NeuroPace (NPCE)?
What is NeuroPace's (NPCE) strategy for growth according to the press release?
What is Amy Treadwell's professional background before joining NeuroPace (NPCE)?
What other recent appointments has NeuroPace (NPCE) made to its management team?
